India Glycols Limited announces an acquisition

Verdict: India Glycols Limited does not appear to retain a controlling stake in Ennature Bio Pharma Limited after the allotment. Ennature’s shares were issued directly to the eligible shareholders of India Glycols in a 1:3 ratio, so ownership of Ennature is dispersed among the same shareholder base rather than being held by India Glycols itself. ^[1]

Final shareholding structure

• Ennature allotted 22,342,255 fully paid-up equity shares of Rs 5 each to shareholders of India Glycols whose names appeared on the register as of 2 September 2026. ^[1]
• The entitlement was one Ennature share for every three India Glycols shares held. ^[1]
• Consequently, the post-allotment ownership of Ennature should broadly mirror the India Glycols shareholder register as of the record date; India Glycols Limited itself is not identified as the allottee in the filing. ^[1]
• The filing does not provide the final category-wise Ennature shareholding pattern after allotment. As an indicative, not record-date-confirmed proxy, India Glycols’ June-quarter shareholding comprised Kashipur Holdings at 49.77%, FPIs at 2.24%, DIIs at 5.22%, and the balance held by other shareholders. ^[2]

Classification

On the disclosed allotment structure, Ennature is not a subsidiary of India Glycols, because India Glycols has not been shown as holding the controlling equity stake. It should also not be classified as an India Glycols associate or joint venture merely because it was demerged from India Glycols. The resulting relationship is better described as a separately owned entity with a common shareholder base, potentially under common promoter influence, subject to the final statutory shareholding and accounting disclosures.

The important distinction is:

• India Glycols: retains its own listed chemicals and related businesses.
• Ennature: separately capitalised bio-pharma and bio-polymers entity, with shares allotted to India Glycols’ shareholders and a proposed separate listing. ^[3]
• Parent-level control: not evidenced for India Glycols.
• Associate/JV status: not established by the allotment; any such classification would require separately disclosed ownership, significant-influence rights or joint-control arrangements.

The Scheme filings do not state Ennature Bio Pharma’s specific revenue or EBITDA contribution for FY25 or FY26. The disclosed material update covers the share allotment and appointment of key personnel, rather than a two-year financial bridge for the Bio Pharma undertaking ^[1]. Without the undertaking-level revenue and EBITDA figures, its contribution to India Glycols’ consolidated financials cannot be calculated reliably.

Quarterly reporting impact: The Scheme has an appointed date of 1 April 2026 ^[4]. Upon effectiveness, the Bio Pharma undertaking is transferred to and vested in Ennature Bio Pharma Limited ^[5]. The transaction was identified as effective from 2 September 2026 ^[6].

Therefore, the first post-demerger quarterly results should reflect:

• India Glycols’ consolidated revenue and EBITDA excluding Ennature’s Bio Pharma operations after the applicable Scheme accounting cut-off.
• A mechanical reduction in reported consolidated revenue and EBITDA, which should not be interpreted as an equivalent deterioration in the continuing India Glycols business.
• A changed business mix and potentially different consolidated margins, because the higher- or lower-margin Bio Pharma contribution will no longer sit within India Glycols.
• Separate disclosure of the demerged undertaking, comparative-period treatment, and any restatement or discontinued-operation presentation, if required under the applicable accounting treatment.

The precise FY27 quarterly presentation—particularly whether the full FY27 year-to-date period is presented retrospectively from the appointed date or only from the effective date—cannot be established from the cited Scheme-update filings.